Glika

Glika is a prescription medication that contains the active ingredient gliclazide, a sulfonylurea‑class antidiabetic agent. It is supplied as oral tablets (strength not specified) and is marketed in the European Union. Glika works by stimulating insulin release from pancreatic beta cells and is used under medical supervision to help control blood glucose in adults with type 2 diabetes mellitus. It requires a prescription and should be taken as directed.

Glika is indicated for the management of blood glucose levels in adults with type 2 diabetes mellitus.

- Used as initial monotherapy when diet, exercise, and weight management do not achieve target glycemic control. - Added to metformin therapy when metformin alone fails to maintain desired HbA1c levels. - Combined with other oral antidiabetic agents such as DPP‑4 inhibitors or SGLT2 inhibitors for complementary glucose‑lowering effects. - Prescribed to reduce fasting plasma glucose and post‑prandial glucose excursions. - Considered in patients who prefer a sulfonylurea with a relatively lower incidence of prolonged hypoglycemia.

Glika may cause a range of adverse effects, which are generally categorized as common or serious based on frequency and clinical significance.

Common: - Mild hypoglycemia presenting as shakiness, sweating, or hunger. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Central nervous system symptoms including headache, dizziness, or fatigue. - Transient visual disturbances such as blurred vision or photophobia. - Weight gain due to increased insulin activity and caloric storage.

Serious: - Severe hypoglycemia that can lead to loss of consciousness, seizures, or requires emergency assistance. - Allergic reactions ranging from skin rash and pruritus to angioedema or anaphylaxis. - Hepatic or pancreatic injury manifested by jaundice, elevated liver enzymes, or pancreatitis symptoms. - Blood dyscrasias including leukopenia, neutropenia, or thrombocytopenia.

Before prescribing Glika, clinicians should evaluate several patient‑specific factors to minimize risks and ensure safe use.

- Assess renal and hepatic function, as impairment may affect drug clearance. - Perform baseline and periodic blood glucose monitoring to detect hypoglycemia early. - Use lower starting doses in elderly patients or those with frailty. - Avoid in individuals with known hypersensitivity to sulfonylureas. - Adjust therapy if concomitant illnesses such as infection or cardiovascular disease increase hypoglycemia risk. - Counsel patients on recognizing and managing low‑blood‑sugar symptoms. - Pregnancy, lactation, and pediatric use have not been established; avoid unless benefits outweigh risks.

Glika can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Other sulfonylureas or meglitinides, which can cause additive hypoglycemia. - Strong CYP2C9 inhibitors such as fluconazole, voriconazole, or amiodarone, which may raise gliclazide plasma levels. - Monoamine oxidase inhibitors (MAOIs), due to potential unpredictable glycemic responses. - Excessive alcohol intake, which can potentiate hypoglycemia.

Use with caution: - Beta‑blockers, because they may mask typical hypoglycemia symptoms. - Thiazide diuretics, which can increase the likelihood of low blood sugar. - Warfarin, as gliclazide may affect INR and require closer monitoring. - Corticosteroids, because they may raise blood glucose and counteract gliclazide’s effect.